Neuronetics (NASDAQ:STIM) and Oncologix Tech (OTCMKTS:OCLG) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, institutional ownership, earnings and dividends.
This table compares Neuronetics and Oncologix Tech’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Neuronetics and Oncologix Tech’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Neuronetics||$52.78 million||1.55||-$24.10 million||($2.69)||-1.63|
Oncologix Tech has lower revenue, but higher earnings than Neuronetics.
Volatility and Risk
Neuronetics has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Oncologix Tech has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500.
This is a summary of current ratings and target prices for Neuronetics and Oncologix Tech, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Neuronetics presently has a consensus price target of $19.50, suggesting a potential upside of 344.19%. Given Neuronetics’ higher probable upside, equities research analysts plainly believe Neuronetics is more favorable than Oncologix Tech.
Institutional and Insider Ownership
78.7% of Neuronetics shares are held by institutional investors. 12.0% of Neuronetics shares are held by insiders. Comparatively, 39.9% of Oncologix Tech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Oncologix Tech beats Neuronetics on 5 of the 9 factors compared between the two stocks.
Neuronetics Company Profile
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrist customers. Neuronetics, Inc. was founded in 2003 and is headquartered in Malvern, Pennsylvania.
Oncologix Tech Company Profile
Oncologix Tech, Inc., a diversified medical holding company, provides health care services in the United States. It offers personal home care services, including daily living assistance, companionship, and homemaker services, as well as Alzheimer's care, home care resource planning, and medical care coordination services. The company also manufactures, markets, and distributes medical technologies and products for skilled nursing facilities, acute and critical care facilities, assisted living facilities, hospitals and medical institutions, federal agencies, home medical care industry, respiratory and therapy- physical/occupational therapy centers. In addition, it distributes and sells home medical equipment for sleep and respiratory therapies; supplies and services durable medical equipment to treat obstructive Sleep Apnea; C-PAP and BiPAP oxygen equipment, a large selection of mask interfaces; and offers personalized treatment plans, as well as monitoring and support services. The company was formerly known as BestNet Communications Corp. and changed its name to Oncologix Tech, Inc. in January 2007. Oncologix Tech, Inc. was founded in 1995 and is based in Lafayette, Louisiana.
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.